These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24134510)

  • 1. PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia.
    Rashid S; Kastelein JJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1567-77. PubMed ID: 24134510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
    Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF
    Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
    Sahebkar A; Watts GF
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ; Lambert G; Dullaart RP
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling.
    Costandi J; Melone M; Zhao A; Rashid S
    Circ Res; 2011 Mar; 108(6):727-42. PubMed ID: 21293001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.
    Melone M; Wilsie L; Palyha O; Strack A; Rashid S
    J Am Coll Cardiol; 2012 May; 59(19):1697-705. PubMed ID: 22554600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia.
    Elshourbagy NA; Meyers HV; Abdel-Meguid SS
    Med Princ Pract; 2014; 23(2):99-111. PubMed ID: 24334831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD; Kim JB; Wasserman SM; Lambert G
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and atherogenic dyslipidemia.
    Bamba V; Rader DJ
    Gastroenterology; 2007 May; 132(6):2181-90. PubMed ID: 17498511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
    Shen L; Peng HC; Nees SN; Zhao SP; Xu DY
    FEBS Lett; 2013 May; 587(9):1271-4. PubMed ID: 23499248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.